Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma.

Joseph R. Mikhael, MD, Sahar Zadeh, A. Keith Stewart, MD, Christine Chen, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, FRCPC, Andrew Winter, BScN, Norman Franke, Donna E. Reece, MD

Blood (2009) 114 (22): 1217.

https://doi.org/10.1182/blood.V114.22.1217.1217

Published: 2009

Journal Articles

Post-Transplant Lymphoproliferative Disorder: Evaluation of Effectiveness of Reduction of Immunosuppression or Systemic Chemotherapy

Parneet K Cheema, MD, Sahar Zadeh, Heather Ross, MD, Edward Cole, MD, Shaf Keshavjee, MD, Gary Levy, MD, Michael Crump, MD

Blood (2008) 112 (11): 229.

https://doi.org/10.1182/blood.V112.11.229.229

Published: 2008

Journal Articles

Second Cancers after Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma (NHL).

Tara Seshadri, MBBS, Melania Pintilie, MSc, Richard Tsang, MD, John Kuruvilla, MD, Sahar Zadeh, BSc, Armand Keating, MD, Michael Crump, MD

Blood (2007) 110 (11): 1673.

https://doi.org/10.1182/blood.V110.11.1673.1673

Published: 2007

Journal Articles

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma: Improved Outcomes in Patients with Longer Disease Free Interval after First ASCT.

Joseph R. Mikhael, MD, Sahar Zadeh, BSc, Sara Samiee, MD, Keith Stewart, MD, Christine Chen, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, Norman Franke, MD, Andrew Winter, BScN, Drew Phillips, Donna Reece, MD

Blood (2007) 110 (11): 946.

https://doi.org/10.1182/blood.V110.11.946.946

Published: 2007

Journal Articles

Age under 40 Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplant Despite High Response Rates.

Parneet K. Cheema, MD, Sahar Zadeh, BSc, Donna Reece, MD, Christine I. Chen, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, Joseph R. Mikhael, MD

Blood (2007) 110 (11): 5123.

https://doi.org/10.1182/blood.V110.11.5123.5123

Published: 2007

Journal Articles

Inferior Progression-Free Survival after Autotransplant for Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma in Patients > 60 Versus ≤ 60 Years of Age.

John Kuruvilla, MD, Vikas Gupta, MD, Yael Zaretsky, MD, Sahar Zadeh, Tracy Nagy, Armand Keating, MD, Michael Crump, MD

Blood (2006) 108 (11): 3068.

https://doi.org/10.1182/blood.V108.11.3068.3068

Published: 2006

NARROW

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma.

Post-Transplant Lymphoproliferative Disorder: Evaluation of Effectiveness of Reduction of Immunosuppression or Systemic Chemotherapy

Second Cancers after Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma (NHL).

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma: Improved Outcomes in Patients with Longer Disease Free Interval after First ASCT.

Age under 40 Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplant Despite High Response Rates.

Inferior Progression-Free Survival after Autotransplant for Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma in Patients > 60 Versus ≤ 60 Years of Age.

Email alerts

ASH Publications

American Society of Hematology

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma.

Post-Transplant Lymphoproliferative Disorder: Evaluation of Effectiveness of Reduction of Immunosuppression or Systemic Chemotherapy

Second Cancers after Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma (NHL).

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma: Improved Outcomes in Patients with Longer Disease Free Interval after First ASCT.

Age under 40 Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplant Despite High Response Rates.

Inferior Progression-Free Survival after Autotransplant for Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma in Patients > 60 Versus ≤ 60 Years of Age.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only